Literature DB >> 24309663

Key roles of adjuvants in modern vaccines.

Steven G Reed1, Mark T Orr, Christopher B Fox.   

Abstract

Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns. This Review outlines the potential benefits of adjuvants in current and future vaccines and describes the importance of formulation and mechanisms of action of adjuvants. Moreover, we emphasize safety considerations and other crucial aspects in the clinical development of effective adjuvants that will help facilitate effective next-generation vaccines against devastating infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24309663     DOI: 10.1038/nm.3409

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  121 in total

Review 1.  Targeting human dendritic cell subsets for improved vaccines.

Authors:  Hideki Ueno; Eynav Klechevsky; Nathalie Schmitt; Ling Ni; Anne-Laure Flamar; Sandra Zurawski; Gerard Zurawski; Karolina Palucka; Jacques Banchereau; Sangkon Oh
Journal:  Semin Immunol       Date:  2011-01-28       Impact factor: 11.130

2.  Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I.

Authors:  Tiziana Di Pucchio; Bithi Chatterjee; Anna Smed-Sörensen; Sandra Clayton; Adam Palazzo; Monica Montes; Yaming Xue; Ira Mellman; Jacques Banchereau; John E Connolly
Journal:  Nat Immunol       Date:  2008-03-30       Impact factor: 25.606

3.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis.

Authors:  C Caux; C Massacrier; B Vanbervliet; B Dubois; I Durand; M Cella; A Lanzavecchia; J Banchereau
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

Review 4.  The mechanism of action of MF59 - an innately attractive adjuvant formulation.

Authors:  D T O'Hagan; G S Ott; E De Gregorio; A Seubert
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

5.  Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations.

Authors:  M Vogelbruch; B Nuss; M Körner; A Kapp; P Kiehl; W Bohm
Journal:  Allergy       Date:  2000-09       Impact factor: 13.146

6.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

7.  Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Authors:  Andreas Wack; Barbara C Baudner; Anne K Hilbert; Ilaria Manini; Sandra Nuti; Simona Tavarini; Hanno Scheffczik; Mildred Ugozzoli; Manmohan Singh; Jina Kazzaz; Emanuele Montomoli; Giuseppe Del Giudice; Rino Rappuoli; Derek T O'Hagan
Journal:  Vaccine       Date:  2007-12-07       Impact factor: 3.641

8.  Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Authors:  Mark T Orr; Christopher B Fox; Susan L Baldwin; Sandra J Sivananthan; Elyse Lucas; Susan Lin; Tony Phan; James J Moon; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  J Control Release       Date:  2013-08-09       Impact factor: 9.776

9.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Nekoye Otsyula; Stacey Gondi; Allan Otieno; Victorine Owira; Esther Oguk; George Odongo; Jon Ben Woods; Bernhards Ogutu; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Charity Maingi; Trudie Lang; Ally Olotu; Philip Bejon; Kevin Marsh; Gabriel Mwambingu; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; David Dosoo; Isaac Asante; George Adjei; Evans Kwara; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Coline Mahende; Edwin Liheluka; Lincoln Malle; Martha Lemnge; Thor G Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Anima Sarfo; Alex Agyekum; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Rutendo Nkomo; Tapiwa Tembo; Gerald Tegha; Mercy Tsidya; Jane Kilembe; Chimwemwe Chawinga; W Ripley Ballou; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Aurélie Olivier; Johan Vekemans; Terrell Carter; David Kaslow; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2012-11-09       Impact factor: 91.245

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  407 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

Review 2.  Recent advances in the molecular design of synthetic vaccines.

Authors:  Lyn H Jones
Journal:  Nat Chem       Date:  2015-12       Impact factor: 24.427

Review 3.  Pediatric Vaccine Adjuvants: Components of the Modern Vaccinologist's Toolbox.

Authors:  David J Dowling; Ofer Levy
Journal:  Pediatr Infect Dis J       Date:  2015-12       Impact factor: 2.129

4.  Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Authors:  Peter H Goff; Tomoko Hayashi; Wenqian He; Shiyin Yao; Howard B Cottam; Gene S Tan; Brian Crain; Florian Krammer; Karen Messer; Minya Pu; Dennis A Carson; Peter Palese; Maripat Corr
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 5.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

6.  Accounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresis.

Authors:  Virginie Jakob; Livia Brunner; Christophe Barnier-Quer; Molly Blust; Nicolas Collin; Lauren Carter; Darrick Carter; Kelly M Rausch; Christopher B Fox
Journal:  Ther Adv Vaccines       Date:  2017-05-03

7.  Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Authors:  Denise L Cecil; Gregory E Holt; Kyong Hwa Park; Ekram Gad; Lauren Rastetter; Jennifer Childs; Doreen Higgins; Mary L Disis
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

Review 8.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

9.  Released Tryptophanyl-tRNA Synthetase Stimulates Innate Immune Responses against Viral Infection.

Authors:  Hyun-Cheol Lee; Eun-Seo Lee; Md Bashir Uddin; Tae-Hwan Kim; Jae-Hoon Kim; Kiramage Chathuranga; W A Gayan Chathuranga; Mirim Jin; Sunghoon Kim; Chul-Joong Kim; Jong-Soo Lee
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

10.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.